Business
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids- Virtual investor and analyst event to be held in July 2021 CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from serious neurological diseases, today reported its first quarter 2021 financial results, program progress and corporate updates. “We are very pleased with the progress we’ve made in the first few months of this year, including receiving IND clearance for our VY-HTT01 program for Huntington’s disease as well as presenting important new results at the ASGCT conference from our next generation, blood brain barrier penetrant AAV capsid program which opens up numerous potential opportunities in CNS diseases,” said Andre Turenne, President and CEO of Voyager. “We look forward to providing updates on these and other programs at our upcoming investor event in July and over the coming months, particularly as we prepare to initiate our planned VYTAL Phase 1/2 clinical trial in Huntington’s disease later this year.” Recent Corporate Highlights and Pipeline Updates VY-HTT01 for Huntington’s Disease In April 2021, the Company announced FDA clearance of its Investigational New Drug (IND) application for VY-HTT01, the Company’s gene therapy candidate for the treatment of Huntington’s disease, and plans to initiate the VYTAL Phase 1/2 clinical trial of VY-HTT01 at multiple US sites in the fourth quarter.The planned VYTAL Phase 1/2 clinical trial is designed as a randomized, open-label study with a concurrent delayed-start control. The trial will evaluate the safety and tolerability of VY-HTT01 in patients with early manifest Huntington’s disease. Secondary endpoints include disease biomarkers and clinical outcome measures.Huntington’s disease is caused by toxic gain-of-function mutations in the huntingtin, or HTT, gene. Preclinical data for VY-HTT01 have shown strong reduction in mutant HTT protein in transgenic animal models of Huntington’s disease, resulting in improvement in disease phenotype. Additional data in non-huma...